Navigasi
Tinjauan Pasaran Penyaring Stok Kalendar Dividen Kalendar Acara Penarafan saham Berita Pasaran
Cuba percuma
ACRA TAK
$14.11 0.29 2.06%
Today share price
USA
Sector: Healthcare Industry: Pharmaceuticals
Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free
Rating Finrange Показатель: 40 %
Market cap

Market capitalization – refers to the total value of all a company's shares of stock. It is calculated by multiplying the price of a stock by its total number of outstanding shares.

22.37B
EV

Enterprise value is a measure of a company's total value, often used as a more comprehensive alternative to equity market capitalization. Enterprise value includes in its calculation the market capitalization of a company but also short-term and long-term debt as well as any cash on the company's balance sheet.
3.87T
Beta

Beta is one of the most popular indicators of risk is a statistical measure. Analysts use this measure often when they need to determine a stock's risk profile.
1.10
Shares

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company’s insiders.
1.59B
YTD

Year to date (YTD) refers to the period of time beginning the first day of the current calendar year or fiscal year up to the current date. he acronym often modifies concepts such as investment returns and price change.
-
Upcoming events All events
No upcoming events scheduled
Overview Financials Key Metrics Dividends Industry overview Events

Stock chart

Stock analysis

Indicator Company Industry
P/E (LTM)

Shows how many years the investor's investment in the company will pay off with a profit over the last 12 months.

Lagi
0.13 -
P/BV (LTM)

Shows the ratio of the market price of the share to the current book value.

Lagi
- 0.78
EV/EBITDA (LTM)

Represents the ratio of the company's value to its pre-tax EBITDA in the last 12 months.

Lagi
3.81 3.81
Net Debt/EBITDA (LTM)

A company's debt ratio, which indicates how long the company will need to run on cash flow in the past 12 months to pay off its own debt.

Lagi
3.79 3.79
ROE (LTM)

Shows the efficiency of using the share capital by the company. In other words, ROE shows how much of the company's net profit for the invested capital over the last 12 months.

Lagi
2.64 -

Price change per year

13.81$ 19.97$
Min Max

Summary analysis

Get access
to the rating of Finrange stocks
With this tariff you will be able to use the service without restrictions, all information will be available
Get 7 days free

Shareholder structure

Revenue and net income

All parameters
Stock news All news
3 Mei в 17:50

Объем торгов на рынках Московской биржи в апреле вырос до 124,9 трлн р

3 Mei в 17:40

США вряд ли смогут расширить собственное обогащение урана к 2028 году - эксперт

3 Mei в 17:35

МОСБИРЖА: ОБЩИЙ ОБЪЕМ ТОРГОВ НА РЫНКАХ МОСКОВСКОЙ БИРЖИ В АПР СОСТАВИЛ 124,9 ТРЛН РУБЛЕЙ - ИФ

3 Mei в 17:30

Цена нефти Brent взяла курс на сильнейшее недельное падение за 3 месяца

3 Mei в 17:30

Электрогенерация в Индии за год выросла на 6,2%, наибольший рост - в атомной отрасли

3 Mei в 17:25

Минтранс РФ изучает законопроект о доступе к осуществлению грузоперевозок автотранспортом

3 Mei в 17:15

ЦБ зафиксировал повышение средней ставки по вкладам в топ-10 банков

3 Mei в 17:15

Активность в сфере услуг США в апреле неожиданно перешла к спаду - ISM

3 Mei в 17:10

Ирак и Казахстан компенсируют недосокращение добычи нефти почти на 1 млн б/с до конца года

3 Mei в 17:10

МВФ ухудшил прогнозы восстановления экономики Молдавии

3 Mei в 17:00

Индекс PMI сектора услуг США в апреле снизился до 51,3 - S&P Global

3 Mei в 17:00

ИРАК И КАЗАХСТАН КОМПЕНСИРУЮТ НЕДОСОКРАЩЕНИЕ ДОБЫЧИ НЕФТИ В РАМКАХ СДЕЛКИ ОПЕК+ ПОЧТИ НА 1 МЛН Б/С ДО КОНЦА ГОДА - ОПЕК

3 Mei в 17:00

Новыми резидентами СЭЗ стали четыре компании, намеренные инвестировать в ДНР

3 Mei в 17:00

"Газпром межрегионгаз" отмечает рост поставок газа в 2024 г. потребителям в России

3 Mei в 16:55

Минэкономразвития РФ предложило бизнесу новый стандарт отчетности об устойчивом развитии

3 Mei в 16:55

Потенциал по продажам в РФ новых электрокаров из КНР низкий - глава "Автодома"

3 Mei в 16:55

Законопроект о бесплатном предоставлении участков потерявшим жилье от стихии внесен в Думу

3 Mei в 16:50

Молдавия и МВФ не смогли договориться о выделении следующего транша финансовой помощи

3 Mei в 16:50

US STOCKS-Уолл-стрит устремилась вверх после трудовой статистики США

3 Mei в 16:35

ЦБ РФ понизил курс доллара на 4-6 мая до 91,69 руб., евро - до 98,56 руб.

About company

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, marketing, and out-licensing of pharmaceutical products worldwide. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the Entyvio, Gattex/Revestive, Alofisel, Natpara, Adynovate/Adynovi, Takhzyro, Elaprase, Vpriv, Gammagard Liquid/Kiovig, Hyqvia, Cuvitru, Albumin/Flexbumin, Ninlaro, and Alunbrig brands. Takeda Pharmaceutical Company has licensing agreements with Denali Therapeutics and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc. and Rani Therapeutics LLC; license and research agreements with The University of Texas MD Anderson Cancer Center, Poseida Therapeutics, Inc., and Arrowhead Pharmaceuticals Inc.; research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and collaboration with Evox Therapeutics Ltd., as well as a licensing agreement with ProThera Biologics Inc. It also has strategic alliances with Egle Therapeutics SAS; Evotec SE; Neurocrine Biosciences, Inc.; Carmine Therapeutics; HemoShear Therapeutics, LLC; KSQ Therapeutics; and Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.
Address:
1-1, Nihonbashi-Honcho 2-chome, Tokyo, Japan, 103-8668
Company name:
Issuer ticker: TAK
ISIN: US8740602052
Country: USA
Exchange: ACRA
Currency: $
IPO date: 2008-10-27
Sector: Healthcare
Industry: Pharmaceuticals
Site: https://www.takeda.com

On which stock exchange are (TAK) stocks traded?

(TAK) stocks are traded on ACRA.

What is the ticker of stocks (TAK)?

The stock ticker of ’s stocks or in other words, the code is TAK. The stocks are currently listed on the ACRA exchange.

In which sector and industry does (TAK) operate?

According to the GICS (Global Industry Classification Standard) classification developed jointly by MSCI and Standard & Poor's, (TAK) belongs to the «Healthcare» sector and the «Pharmaceuticals» industry.

In what currency are (TAK) stocks traded?

(TAK) stocks are traded on the ACRA exchange in dollars.

What is the price of (TAK) stocks today?

The current price of stocks on 03.05.2024 is 14.11 dollars. per share.

What is the dynamics of (TAK) stocks from the beginning of the year?

(TAK) quotes have increased by 0% from the beginning of the year up to 14.11 dollars. per 1 stocks.

How much did (TAK) stocks increase in мае 2024?

This month (TAK) quotes have increased by 0% to 14.11 dollars. per share.

How much are (TAK) stocks worth?

Today, on October, 03.05.2024 ’s (TAK) stocks cost 14.11 dollars..

What is the market capitalization of (TAK)?

Capitalization is the market value of (TAK) is calculated as the number of issued stocks multiplied on the current quotation price. Thus, on 03.05.2024, the market capitalization of (TAK) is estimated at about 22366014980 dollars.